There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Moderna (MRNA – Research Report) and Silverback Therapeutics (SBTX – Research Report) with bullish sentiments.
Goldman Sachs analyst Salveen Richter maintained a Buy rating on Moderna today and set a price target of $461.00. The company’s shares closed last Thursday at $440.30, close to its 52-week high of $497.49.
According to TipRanks.com, Richter is a 5-star analyst with an average return of
Currently, the analyst consensus on Moderna is a Hold with an average price target of $328.00, implying a -23.9% downside from current levels. In a report issued on September 9, Brookline Capital Markets also maintained a Buy rating on the stock with a $468.00 price target.
Silverback Therapeutics (SBTX)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Silverback Therapeutics, with a price target of $52.00. The company’s shares closed last Thursday at $11.83.
According to TipRanks.com, White is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Silverback Therapeutics with a $50.33 average price target, a 238.0% upside from current levels. In a report issued on September 13, JonesTrading also reiterated a Buy rating on the stock with a $50.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MRNA: